Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Antiviral activity of a small-molecule inhibitor of filovirus infection.

Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S.

Antimicrob Agents Chemother. 2010 May;54(5):2152-9. doi: 10.1128/AAC.01315-09. Epub 2010 Mar 8.

2.

Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β -/- interferon receptor-deficient mice.

Lever MS, Piercy TJ, Steward JA, Eastaugh L, Smither SJ, Taylor C, Salguero FJ, Phillpotts RJ.

J Med Microbiol. 2012 Jan;61(Pt 1):8-15. doi: 10.1099/jmm.0.036210-0. Epub 2011 Aug 18.

PMID:
21852521
3.

Drug targets in infections with Ebola and Marburg viruses.

Gene OG, Julia BE, Vanessa MR, Victoria WJ, Thomas GW, Lisa HE.

Infect Disord Drug Targets. 2009 Apr;9(2):191-200. Review.

PMID:
19275706
4.

Development and characterization of a mouse model for Marburg hemorrhagic fever.

Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, Reed DK, VanTongeren SA, Mech CA, Bavari S.

J Virol. 2009 Jul;83(13):6404-15. doi: 10.1128/JVI.00126-09. Epub 2009 Apr 15.

5.

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S.

Nat Med. 2010 Sep;16(9):991-4. doi: 10.1038/nm.2202. Epub 2010 Aug 22.

PMID:
20729866
6.

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.

Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S.

Nature. 2014 Apr 17;508(7496):402-5. doi: 10.1038/nature13027. Epub 2014 Mar 2.

PMID:
24590073
7.

Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.

Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L.

J Virol. 2015 Oct;89(19):9932-8. doi: 10.1128/JVI.01337-15. Epub 2015 Jul 22.

8.

Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.

Panchal RG, Reid SP, Tran JP, Bergeron AA, Wells J, Kota KP, Aman J, Bavari S.

Antiviral Res. 2012 Jan;93(1):23-9. doi: 10.1016/j.antiviral.2011.10.011. Epub 2011 Oct 18.

PMID:
22027648
9.

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H.

J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.

10.

Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines.

Marzi A, Kercher L, Marceau J, York A, Callsion J, Gardner DJ, Geisbert TW, Feldmann H.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S404-9. doi: 10.1093/infdis/jiv188. Epub 2015 May 28.

11.

Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus.

Qiu X, Wong G, Audet J, Cutts T, Niu Y, Booth S, Kobinger GP.

J Virol. 2014 Nov;88(21):12703-14. doi: 10.1128/JVI.01643-14. Epub 2014 Aug 20.

12.

Filovirus infection of STAT-1 knockout mice.

Raymond J, Bradfute S, Bray M.

J Infect Dis. 2011 Nov;204 Suppl 3:S986-90. doi: 10.1093/infdis/jir335.

PMID:
21987780
13.

Development of treatment strategies to combat Ebola and Marburg viruses.

Paragas J, Geisbert TW.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):67-76. Review.

PMID:
16441210
14.

Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents.

Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S421-9.

PMID:
17940979
15.

Inhibition of filovirus replication by the zinc finger antiviral protein.

Müller S, Möller P, Bick MJ, Wurr S, Becker S, Günther S, Kümmerer BM.

J Virol. 2007 Mar;81(5):2391-400. Epub 2006 Dec 20.

16.

A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.

Mire CE, Geisbert JB, Versteeg KM, Mamaeva N, Agans KN, Geisbert TW, Connor JH.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S384-8. doi: 10.1093/infdis/jiv126. Epub 2015 May 9.

17.

The role of reverse genetics systems in determining filovirus pathogenicity.

Theriault S, Groseth A, Artsob H, Feldmann H.

Arch Virol Suppl. 2005;(19):157-77. Review.

PMID:
16355872
18.

A limited structural modification results in a significantly more efficacious diazachrysene-based filovirus inhibitor.

Selaković Z, Opsenica D, Eaton B, Retterer C, Bavari S, Burnett JC, Solaja BA, Panchal RG.

Viruses. 2012 Aug;4(8):1279-88. doi: 10.3390/v4081279. Epub 2012 Aug 15.

19.

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.

20.

A small nonhuman primate model for filovirus-induced disease.

Carrion R Jr, Ro Y, Hoosien K, Ticer A, Brasky K, de la Garza M, Mansfield K, Patterson JL.

Virology. 2011 Nov 25;420(2):117-24. doi: 10.1016/j.virol.2011.08.022. Epub 2011 Sep 28.

Supplemental Content

Support Center